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THE current  study  was  undertaken  to  evaluate  the
effects  of  granulocyte-macrophage  colony-stimulat-
ing factor (GM-CSF) and cyclic AMP (cAMP) signaling
interaction  on  human  neutrophil  apoptosis,  either
occurring spontaneously or induced  by Fas antigen
activation. Results show that GM-CSF, dibutyryl cAMP
(a cAMP analog) and forskolin (an adenylate cyclase
activator) are all able to suppress spontaneous neu-
trophil cell death. Of note however, when GM-CSF is
used in combination with cAMP-elevating agents, an
additive effect on neutrophil survival is observed with
dibutyryl  cAMP  only,  whereas  supplementation  of
cell cultures with GM-CSF and forskolin results in a
progressive reduction of antiapoptotic effects exerted
by the single compounds. Moreover, although dibu-
tyryl cAMP and forskolin do not affect Fas-triggered
apoptotic events, they are still able to modulate the
GM-CSF capacity to prolong neutrophil survival fol-
lowing anti-Fas IgM cell challenge, with effects similar
to  those  respectively  exerted  on  spontaneous  neu-
trophil apoptosis. The data indicate that GM-CSF may
negatively modulate the cAMP-mediated antiapoptotic
pathway in human neutrophils, likely via the inhibi-
tion of adenylate cyclase activity. This would prevent
an abnormal neutrophil survival as a result of cAMP
signaling stimulation, which provides a novel insight
into the role of GM-CSF as a physiological regulator of
myeloid cell turnover.
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Introduction
Polymorphonuclear leukocytes (PMN) play a critical
role  in  host  defense  against  invading  microorgan-
isms,
1 as well as in local and systemic inflammatory
diseases.
2 The maintenance of circulating PMN levels
within physiologic limits is thus crucial for the host.
Since mature neutrophils are terminally differentiated
cells incapable of self-renewal,
3 such an event is made
possible  by  a  continuous  highly  controlled  balance
between  the entry of newborn  cells into the blood
and the elimination of senescent PMN in the tissues.
In  the  last  few  years,  large  evidence  has  been
provided that programmed cell death or apoptosis is
the  major  mechanism  for  limiting  PMN  amount  in
vivo.
4–7 Different from necrosis, apoptosis is charac-
terized  by  specific  morphologic  and  biochemical
events including cell shrinkage, cytoplasmic vacuola-
tion,  membrane  blebbing  (zeiosis),  chromatin  con-
densation and nuclear fragmentation associated with
endonucleolytic DNA  cleavage.
8 Apoptotic PMN are
then recognized and engulfed by macrophages via the
vitronectin  receptor,
9 thus  preventing  the  possible
occurrence  of  tissue  damage  as  a  consequence  of
toxic product leakage from destroyed cells.
Although  neutrophils  appear  to be committed to
apoptotic cell death in vivo as well as in vitro, this
process  is  susceptible  to  modulation  by  different
compounds. In this context, it has been reported that
Fas antigen engagement on the PMN surface, either
by Fas ligand binding or binding of agonistic anti-Fas
IgM antibody, markedly accelerates neutrophil apop-
tosis.
10,11 On  the  contrary,  many  PMN  activators,
including  proinflammatory  cytokines  and  bacterial
products are all able to prolong the life span and the
functional  activity  of  PMN  in  vitro.
4,10–14 In  this
regard,  cyclic  AMP  (cAMP)  has  been  shown  to
modulate the apoptotic process, exhibiting a cell-type
dependent  effect.  Thus,  whereas  cAMP-elevating
agents accelerate apoptosis in a variety of cell types,
including  thymocytes  and  B  lymphocytes,
15,16 they
suppress  neutrophil  cell  death  occurring  sponta-
neously in vitro.
17,18
In  spite  of  these  findings,  the  mechanisms  by
which  the  different  molecules  influence  neutrophil
survival are largely unknown. In this study, we have
investigated  the  effects  of  granulocyte-macrophage
colony-stimulating factor (GM-CSF)- and  cAMP-medi-
ated  pathway  interaction  on  apoptotic  outcome  of
human  neutrophils. To  this  aim,  dibutyryl  cAMP  (a
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activator), used alone or in combination with GM-CSF ,
have been  supplemented to PMN cell cultures, and
the occurrence of apoptosis, either spontaneous or
induced by Fas antigen activation, has been evaluated
on the basis of typical morphological changes as well
as quantitative assay of DNA fragmentation.
Materials and Methods
Cell purification
Human neutrophils were isolated from the peripheral
blood of 25 healthy asymptomatic donors by a two
stage procedure. First, venous blood, diluted 1:4 with
phosphate buffered saline (0.02 M PBS; pH 7.2), was
fractionated  by  Ficoll  gradient  centrifugation  (Ser-
omed-Biochem  KG,  Berlin,  Germany)  at  170 g for
45 min.
19 Thereafter,  the  cell  pellets  were  washed
twice  with  PBS  and  mixed  with  a  6%  dextran
(40,000 mw)  solution.  Following  sedimentation  for
1 h at 37°C, the PMN-rich supernatants were collected
and centrifuged at 400 g for 10 min. Pellets were then
subjected  to  hypotonic  lysis  of  erythrocytes  and
finally  resuspended  in  RPMI-1640  (Sigma  Chemical
Co,  Milan,  Italy)  supplemented  with  penicillin
(100 IU/ml),  streptomycin  (100m g/ml),  L-glutamine
(2 mM)  and  10%  heat-inactivated  foetal  calf  serum
(FCS) (complete medium). The preparation contained
more than 95% PMN, of which more than 90% were
neutrophils, as determined by May Gr¨ unwald-Giemsa
staining of cytocentrifuged samples.
All  reagents  were  LPS-free,  as  assessed  by  the
Limulus amoebocyte lysate assay (Sigma).
Culture conditions
PMN (10
6 cells/well in a total volume of 300 m l/well)
were cultured at 37°C in humidified air containing 5%
CO2 in  24-well  cell  culture  clusters  (Costar,  Milan,
Italy),  in  the  absence  or  presence  of  GM-CSF
(1000 UI/ml),  dibutyryl  cAMP  (23 10
–6 M  up  to
23 10
–3 M),  forskolin  (10
–6 M  up  to  10
–4 M)  (all
purchased from Sigma), or a combination of GM-CSF
and  either  of  cAMP-elevating  agents.  After  24 h
incubation,  cells  were  removed,  washed  once  in
RPMI-1640  and  used  for  the  different  apoptotic
assays. In another series of experiments, the effects of
cAMP elevating agents on GM-CSF capacity to inhibit
neutrophil apoptosis induced by Fas was evaluated.
PMN cell cultures were thus pretreated for 2 h with
GM-CSF or dibutyryl cAMP and forskolin, both used
alone  or  in  combination  with  GM-CSF ,  and  then
supplemented  with  murine  monoclonal  antibody
(mAb) CH-11 (anti-human Fas IgM inducing apopto-
sis; 150 ng/ml) for a further 12 h of incubation, before
being  processed for apoptotic analysis as described
below.
Analysis of apoptotic cellular morphology of
PMN
For  the  analysis  of  apoptotic  morphology,  cytospin
preparations  of  PMN  were  stained  with  May  Gr¨ un-
wald-Giemsa  and  examined  by  oil-immersion  light
microscopy at 6003 final magnification. Five hundred
cells were counted per sample and data are reported
as percentage of cells with apoptotic morphology, as
assessed according to the following criteria: nuclear
condensation  eventually  resulting  in  apoptotic  bod-
ies,  decrease  in  cell  size  and  cytoplasmic
vacuolation.
8
Quantitation of DNA fragmentation
Quantitation of DNA fragmentation was performed by
determination of fractional solubilized DNA by diph-
enylamine assay, as described elsewhere.
20 In  brief,
33 10
6 PMN were centrifuged for 10 min at 200 g and
the resulting cell pellets lysed by addition of 0.5ml
TTE solution  (10 mM Tris HCl pH  7.4;  1 mM  EDTA;
0.2%  Triton  X-100).  Thereafter,  lysates  were  cen-
trifuged  for  10 min  at  13,000 g to  separate  intact
chromatin (pellet) from soluble low molecular weight
DNA (supernatant). Supernatants were then carefully
transferred  to  new  tubes  whereas  pellets  were
supplemented  with  0.5 ml TTE  solution. After  over-
night  precipitation  with  0.5 ml  of  25%  TCA  (tri-
chloroacetic acid), DNA was centrifuged for 10 min at
13,000 g, supernatants were aspirated and discarded,
and pellets were added with 80 m l of 5% TCA before
being placed in a heating block for 15 min at 90°C to
hydrolyze  DNA.  Each  tube  was  then  supplemented
with 160 m l of freshly prepared diphenylamine (DPA)
reagent  [150 mg  DPA  (Sigma)  in  a  polypropylene
tube;  10 ml  glacial  acetic  acid;  150 m l  concentrated
sulfuric  acid;  50 m l  acetaldehyde  (16 mg/ml)]  and
colour was allowed to develop for 4 h at 37°C. Two
hundred  m l  of  coloured  solution  was  finally  trans-
ferred to wells of a 96-well flat-bottomed ELISA plate
and  the  optical  density  (OD)  was  determined  in  a
multiwell scanning spectrophotometer (Titertek Mul-
tiscan  MCC;  Flow  Laboratories,  Milan,  Italy),  at  a
wavelength  of  620 nm.  Data  are  reported  as  the
percentage of soluble, low molecular weight DNA in
comparison to total DNA.
Statistical analysis
Statistical  analysis  was  performed  by  means  of  a
paired t-test. P values <0.05 were taken as statistically
significant.
Results
In agreement with previous reports,
4,10–13,17,18 here
we find that both GM-CSF and cAMP-elevating agents
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particular reference to the latter compounds, a dose-
dependent  inhibition  of  neutrophil  cell  death  is
observed  following  supplementation  of  PMN  cell
cultures with dibutyryl cAMP, whereas the addition of
forskolin  significantly  delays  neutrophil  apoptosis
only  at  the  highest  concentrations  used  (see Table
1).
To gain insight into the mechanisms by which these
molecules influence apoptosis, the effects of cAMP-
and GM-CSF-dependent pathway interaction on neu-
trophil cell death, either occurring spontaneously or
induced by Fas antigen activation, have been assessed
by means of DNA fragmentation analysis. As depicted
in  Fig.  1A,  suboptimal  concentrations  of  dibutyryl
cAMP  significantly  enhances  GM-CSF  capacity  to
suppress spontaneous neutrophil apoptosis, whereas
higher concentrations prolong PMN survival as effec-
tively  as  the  cyclic  nucleotide  alone.  Interestingly,
treatment of PMN cell cultures with forskolin and GM-
CSF gives rise to an opposite apoptotic outcome, with
the  cytokine  suppressing  the  antiapoptotic  activity
exerted by forskolin, and increasing levels of forskolin
determining  a  progressive  reversal  of  cell  survival
advantage provided by GM-CSF (Fig. 1B).
As  far  as  the  effects  on  Fas-triggered  neutrophil
apoptosis is concerned, Fig. 2 illustrates that unlike
GM-CSF , which determines a significant inhibition  of
apoptotic  events,  neither  dibutyryl  cAMP  nor  for-
skolin, even used at the highest concentrations, are
able  to  reduce  the  appearance  of  DNA  cleavage
products,  after  PMN  incubation  for  12 h.  Of  note
however is that both cAMP-elevating agents prove to
be effective in modulating the antiapoptotic activity
of  GM-CSF,  with  dibutyryl  cAMP  enhancing  and
forskolin inhibiting the cytokine capacity to prolong
PMN  survival  following  anti-Fas  IgMmAb  cell  chal-
lenge (Fig. 3).
Discussion
Neutrophils have the shortest life span among leuko-
cytes. Similarly, they rapidly die when maintained in
vitro, exhibiting the morphological features of cells
undergoing apoptosis.
4 –7 Our data confirm the capac-
GM-CSF and cAMP effects on neutrophil apoptosis
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Table 1. Modulating effects of GM-CSF and cAMP-elevating
agents on spontaneous neutrophil apoptosisa





23 10–6 M 50.4±5.1* 43.6±4.8*
23 10–5 M 40.8±4.6* 36.7±3.2*
23 10–3 M 11.9±1.9* 12.6±1.7*
Forskolin
10–6 M 60.2±6.8 50.2±5.8
10–5 M 57.9±4.9 48.6±6.2
10–4 M 39.6±3.4* 34.2±3.6*
aNeutrophils were cultured in vitroin the absence or presence of GM-
CSF (1000UI/ml), dibutyryl cAMP or forskolin. After 24h of incuba-
tion, aliquots of PMN were recovered and further processed for the
assessment  of  apoptotic  morphology,  or  the  analysis  of  DNA
fragmentation. Data represent the mean±SD of percentage of cells
showing  features  of  apoptosis,  or  ratio  of  low  to  high  molecular
weight DNA expressed as a percentage, in 25 independent donors.
Significance  versus  homologous  cells  cultured  in  medium  alone:
*p<0.001.
FIG. 1. Effects of GM-CSF and cAMP-elevating agent interaction on spontaneous neutrophil apoptosis. Neutrophils were
cultured in vitro for 24h in the absence or presence of GM-CSF (1000UI/ml; white columns), dibutyryl cAMP (panel A) and
forskolin (panel B) (both represented with a solid line), or a combination of GM-CSF and either of cAMP-elevating agents
(dotted columns).  Cells were then recovered  and  further processed  for the analysis  of DNA fragmentation. Results  are
expressed as percentage of inhibition (mean±SD) of low to high molecular weight DNA ratio in treated compared to untreated
cell cultures, and are obtained from 12 independent donors. Significance versus cell suspensions treated with GM-CSF only:
**p<0.01 and *p<0.001; significance versus PMN treated with homologous concentrations of dibutyryl cAMP or forskolin:
#p<0.001.ity of GM-CSF
4,10 –13 and cAMP-elevating agents
17,18 to
delay this process. Nevertheless, the GM-CSF inhibi-
tion of forskolin-mediated antiapoptotic activity  out-
lines  the  possibility  that  the  cytokine  acts  as  a
physiological  regulator  of  cAMP-signaling  in  human
neutrophils. The  additive  effects  between  dibutyryl
cAMP, which bypasses the adenylate cyclase, and GM-
CSF  indicate  that  such  an  inhibitory  function  may
involve  the adenylate  cyclase,  a  key  enzyme in  the
cAMP-mediated  pathway,  further  suggesting  that  a
common  transductional  step  is  likely  to  occur  at  a
later phase during the signaling events triggered by
the two molecules.
Previous  reports  on  the  role  of  GM-CSF  in  the
adenylate cyclase and the cAMP transduction pathway
have led to contrasting results, strictly related to cell
lineage.
21–24 Of  note  however,  our  data  are  in
accordance  with  studies  on  human  leukemia  cells,
showing a significant reduction of cAMP intracellular
levels following cytokine cell challenge.
23 Wei et al.
25
have recently  found  that  GM-CSF-mediated  suppres-
sion  of  neutrophil  apoptosis  is  dependent  on  the
activation of Lyn kinase, a member of the Src tyrosine
kinase family. Whether this early signal pathway may
account  for  the  inhibition  of  adenylate  cyclase
induced  by  GM-CSF  will  certainly  be  a  subject  of
further investigation.
Although  the  nature  of  the  saturable  enzymatic
activity  common  to  GM-CSF-  and  cAMP-mediated
pathways  has  not  been  directly  investigated  in  this
study, it is tempting to hypothesize that such a role
might be carried out by a transcription factor, called
CREB  (cAMP-response  element-binding  protein),
whose activation  might, in  turn,  be responsible  for
the expression of genes involved in the regulation of
apoptotic phenomenon. Besides PKA-induced CREB
activation, which represents the way through which
cAMP signals reach the nucleus,
26 it has, in fact, been
recently demonstrated that phosphorylation of CREB
is required for transcriptional activation  in response
to  GM-CSF,
27 such  an  effect  occurring  via  a  PKA-
independent  pathway.
24 Moreover,  by  using  a  thy-
moma cell line system, Dowd et al.
28 have reported
that this protein is actively involved in the apoptotic
events induced by cAMP, glucocorticoids or calcium
increase.  More  generally,  CREB  phosphorylation
might thus represent a transductional step common
C. Tortorella et al.
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FIG. 2. Differential effects of GM-CSF and cAMP-elevating agents on Fas-induced neutrophil apoptosis. PMN were pretreated
with or without GM-CSF (1000UI/ml), dibutyryl cAMP (23 10–3 M) or forskolin (10–4M) for 2h, and then supplemented withmAb
CH-11 (150ng/ml) or medium alone for a further 12h of incubation, before DNA extraction and analysis. Results represent the
ratio of DNA cleavage products to high molecular weight DNA expressed as percentage (mean±SD), in 15 healthy volunteers.
Significance versus control: *p<0.001.
FIG. 3. Modulating effects of cAMP-elevating agents on GM-
CSF-mediated inhibition of Fas-induced neutrophil apoptotic
death. PMN were pretreated for 2h with GM-CSF (1000UI/
ml), either used alone (white column) or in combination with
dibutyryl  cAMP  (23 10–3M)  or  forskolin  (10–4M)  (dotted
columns),  before  the  addition  ofmAb  CH-11  (150ng/ml).
After  a  12h  culture,  cells  were  recovered  and  further
processed  for  DNA  fragmentation  analysis.  Results  are
expressed as percentage of inhibition (mean±SD) of low to
high  molecular  weight  DNA ratio induced by  the various
substances in 12 independent donors. Significance versus
homologous  cells suspensions treated with GM-CSF only:
*p<0.001.to  a  variety  of  molecules  influencing  apoptosis,  its
activation  determining  either  apoptotic  or  rescuing
effects according to the cell type involved.
Other than being inhibited in its activity by GM-CSF ,
forskolin may in turn reduce the cytokine capacity to
suppress  neutrophil  apoptosis. The  only  reasonable
explanation  for  such an  effect  is  that  the  molecule
may interfere with the signaling pathway triggered by
GM-CSF , either inhibiting some enzymatic activity or
activating  some  inhibitory  molecule.  Regardless  of
either  possibility,  this  finding  would  imply  a  novel
forskolin function, which adds to that already known
of adenylate cyclase activator.
We have previously reported
10 with other groups
11
that  Fas-triggered  neutrophil  apoptosis  may  be  par-
tially  suppressed  by  some  proinflammatory  media-
tors, including GM-CSF as well as granulocyte-CSF and
lipopolysaccharide. In the current study, we further
extend  these  findings,  showing  that  although  dibu-
tyryl  cAMP  or  forskolin  does  not  influence  the
apoptotic events  induced by Fas antigen  activation,
they  can  still  modulate  the  antiapoptotic  activity
mediated  by  GM-CSF,  with  effects  similar  to  those
respectively exerted on spontaneous neutrophil cell
death. Accordingly, it is conceivable to suppose that
cAMP-elevating agents, being per se unable to affect
the Fas-induced apoptotic outcome, may still interfere
with the Fas signaling at a subliminar level, making it
more  or  less  responsive  to  GM-CSF  activity.  An
alternative possibility may however arise from a more
detailed analysis of results. Whether a 12 h incubation
time is sufficient to induce a Fas-mediated apoptotic
death in the majority of cells, such a time still allows
for the occurrence of spontaneous apoptotic events
in about 25% of neutrophils, as evaluated from control
cultures in the absence of anti-Fas mAb (see Fig. 2).
Under  these  experimental  conditions,  it  is  thus
possible that the rescuing effect of GM-CSF is related
to  the  antiapoptotic  activity  exerted  towards  the
neutrophil  population  undergoing  a  spontaneous
apoptotic  death,  rather  than  to  its  capacity  to
interfere  with  the  Fas  signaling,  as  previously  sup-
posed.
10,11 Accordingly,  the  different  modulation
exerted  by  GM-CSF  and  cAMP  on  neutrophil  cell
death  in  ‘Fas-treated’  cultures  might  rely  on  the
different time course activity of the two molecules on
spontaneous apoptotic events. To support this view,
in  parallel experiments, we  find  that  the inhibitory
effect of GM-CSF on spontaneous neutrophil apopto-
sis occurs very early in culture, peaks at 12 h and then
gradually  decreases,  whereas  cAMP-mediated  anti-
apoptotic activity starts later, but is still evident after
a 48 h incubation time (data not shown).
Taken  together,  the  data  are  consistent  with  the
conclusion that even though both cAMP and GM-CSF
are able to  inhibit  neutrophil cell death, a  negative
modulation  of  cAMP  signaling  occurs  as  a  con-
sequence of cytokine cell challenge. Since adenylate
cyclase  activation  is  a  nonspecific  event  and  cAMP
acts as second messenger for a variety of molecules,
29
the  in  vivo administration  of GM-CSF may  have an
important  counterpart,  by  preventing  an  abnormal
neutrophil survival, and then favouring the increase
of newborn PMN at blood level.
30
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